Obesity Pipeline Summary

DelveInsight’s, “Obesity – Competitive Landscape and Clinical Trial Analysis, 2026” report provides comprehensive insights about 200+ companies and 200+ drugs in Obesity Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Obesity: Understanding

Obesity: Overview

Obesity is a chronic, relapsing, adiposity-based disease characterized by excessive or abnormal body fat that can impair physical health and increase morbidity and mortality. Traditionally, obesity in adults is defined using BMI ≥30 kg/m², although newer frameworks emphasize that BMI alone does not capture fat distribution or obesity-related organ dysfunction. Central adiposity, excess body fat and associated complications are increasingly incorporated into diagnosis.

Common signs and symptoms include excess body weight, increased waist circumference, breathlessness, fatigue, reduced physical mobility, joint discomfort and sleep disturbances. Obesity is multifactorial and results from interactions among genetic susceptibility, energy imbalance, dietary patterns, physical inactivity, environmental factors, medications, socioeconomic conditions and neuroendocrine regulation.

Pathophysiologically, obesity develops when energy intake chronically exceeds energy expenditure, resulting in adipocyte enlargement and expansion of adipose tissue. Excess adiposity can promote chronic low-grade inflammation, insulin resistance, altered adipokine signaling and metabolic dysfunction, contributing to type 2 diabetes, cardiovascular disease, fatty liver disease, sleep apnoea and musculoskeletal disorders.

Diagnosis of obesity begins with assessment of body mass index (BMI), with a BMI ≥30 kg/m² generally classified as obesity in adults; however, BMI alone does not accurately reflect body-fat distribution or health risk. Waist circumference is therefore often measured to identify central or visceral adiposity, while body-composition techniques such as DXA or bioelectrical impedance may be used when additional assessment is required.

Clinical evaluation includes medical and family history, weight trajectory, diet, physical activity, medications, sleep, and potential secondary causes such as endocrine disorders. Clinicians also assess obesity-related complications through blood pressure measurement and laboratory tests such as glucose/HbA1c, lipid profile and liver-function tests. Increasingly, diagnosis emphasizes the amount and distribution of excess adiposity together with its impact on organ function and overall health, rather than relying on BMI alone.

Treatment is individualized and aims not only to reduce weight but also to improve obesity-related complications and overall health. Lifestyle management, including nutritional intervention, physical activity and behavioral support, remains foundational; however, long-term physiological adaptations can make sustained weight loss difficult. Pharmacotherapy may be added when clinically appropriate, with current options including GLP-1 receptor agonists and GLP-1/GIP-based therapies such as semaglutide and tirzepatide, alongside other approved anti-obesity medicines. For selected patients with severe or complicated obesity, metabolic/bariatric surgery provides the most durable weight-loss option.

Report Highlights

• In August 2026, Neurocrine Biosciences, Inc. announced the initiation of a Phase I first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity.
• In August 2026, Ascletis Pharma Inc. announced that following the Investigational New Drug (IND) clearance by the US Food and Drug Administration (FDA), it has initiated two Phase I studies in the US for the treatment of obesity: ASC36, a once-monthly to once-quarterly next-generation amylin receptor peptide agonist and ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and GLP-1R/GIPR peptide agonist ASC35.
• In August 2026, MBX Biosciences, Inc. reported that the initial Phase I data for MBX 4291 supports potential for once-monthly dosing. Preliminary blinded data from the ongoing Phase I trial of MBX 4291 in adults with obesity demonstrated mean weight loss of 7% (range, 0–16%) at eight weeks (n=8, including 2 placebo) in the first multiple ascending dose (MAD) Part B cohort, with MBX 4291 generally well tolerated through eight weeks.
• In July 2026, Eli Lilly and Company announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase III trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease.
• In June 2026, iBio, Inc. announced the dosing of the first participant in its Phase I clinical trial of IBIO-600, the Company’s most advanced obesity and cardiometabolic asset and its first program to enter human clinical development.
• In May 2026, Eli Lilly and Company announced positive topline results from TRIUMPH-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.
• In March 2026, Viking Therapeutics, Inc. announced the completion of patient enrollment in its Phase III VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
• In January 2026, Alveus Therapeutics Inc. announced its launch with a USD 159.8 million Series A financing. Proceeds from the financing will support Phase II clinical development of ALV-100, the company's lead program.
• In January 2026, Roche announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity.
• In January 2026, Alveus Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ALV-100, the company’s lead investigational therapy for chronic weight management, enabling initiation of a Phase Ib clinical study.
• In December 2025, Wave Life Sciences Ltd. announced positive interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007 for the treatment of obesity. In this interim assessment, a single 240 mg dose of WVE-007 led to an improvement in body composition characterized by reductions in total and visceral fat mass at three months and an increase in lean mass. There was also a favorable safety profile as well as durable reductions in serum Activin E that support potential once or twice-yearly dosing.

Obesity: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, founded in 1876 and focused on discovering, developing, manufacturing, and commercializing innovative medicines. The company has a strong presence across diabetes, obesity, oncology, immunology, neuroscience, and other major therapeutic areas. Lilly has a global commercial and R&D footprint, with products marketed across approximately 90 countries and clinical research conducted in more than 55 countries. Its portfolio includes several leading medicines and a broad pipeline of innovative therapies addressing significant unmet medical needs.

Product Description: Orforglipron

Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly for the treatment of Obesity. It activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon secretion, and slow gastric emptying, thereby improving glycemic control. Unlike injectable GLP-1 therapies, orforglipron is designed for oral administration without the need for injection or fasting requirements. In August 2026, the UK MHRA authorised orforglipron for adults with insufficiently controlled Obesity, making the UK the first country in Europe to approve it for this indication.

2. Company Overview: Novo Nordisk

Novo Nordisk A/S is a global healthcare company founded in 1923 and headquartered in Denmark, with a long-standing focus on developing innovative medicines for serious chronic diseases. Its core therapeutic areas include diabetes, obesity, rare diseases, and cardiovascular and emerging therapy areas. The company has a broad international presence, with products marketed in around 170 countries and operations in approximately 80 countries. Novo Nordisk combines scientific innovation with large-scale manufacturing and R&D capabilities to develop and expand access to advanced treatments worldwide.

Product Description: Wegovy

Wegovy® (semaglutide) is a GLP-1 receptor agonist developed by Novo Nordisk for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The therapy works by activating GLP-1 receptors to reduce appetite and food intake, supporting sustained weight loss when combined with a reduced-calorie diet and increased physical activity. In the U.S., Wegovy is available as a once-weekly subcutaneous injection, while the FDA approved a once-daily 25 mg oral tablet in December 2025. The oral formulation demonstrated approximately 17% mean weight loss at 64 weeks in the Phase III OASIS 4 trial.

Obesity: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company established in 1876 and headquartered in Indianapolis, Indiana, dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines. Its key therapeutic focus areas include diabetes, obesity, oncology, immunology, and neuroscience, among others. Lilly maintains a broad international commercial and R&D presence, with its medicines available in around 90 countries and clinical research conducted across more than 55 countries. The company has a diversified portfolio of established therapies alongside a robust pipeline targeting significant unmet medical needs.

Product Description: Retatrutide

Retatrutide is an investigational once-weekly injectable triple agonist developed by Eli Lilly that simultaneously activates the GIP, GLP-1, and glucagon receptors for the treatment of obesity. It is designed to promote weight loss through complementary effects on appetite, glucose metabolism, and energy expenditure. In Phase III obesity trials, retatrutide demonstrated significant reductions in body weight and HbA1c, with results supporting its continued development as a potential treatment for obesity and related metabolic conditions. Retatrutide remains investigational and is not yet approved for obesity.

2. Company Overview: Roche

Roche is a global healthcare company founded in 1896 and headquartered in Basel, Switzerland, with operations spanning pharmaceuticals and diagnostics. The company develops innovative medicines across areas including oncology, immunology, neuroscience, ophthalmology, infectious diseases, and cardiovascular and metabolic disorders. Roche combines pharmaceutical research with diagnostic technologies to advance personalised healthcare and improve patient outcomes. With a presence in more than 100 countries and over 100,000 employees worldwide, Roche is one of the world's leading biotechnology and in-vitro diagnostics companies.

Product Description: Enicepatide

Enicepatide (CT-388) is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist being developed by Roche for chronic weight management in people with obesity or overweight. It is designed to activate both GLP-1 and GIP receptors while minimising β-arrestin recruitment, potentially enabling sustained receptor activity. Enicepatide has demonstrated significant weight-loss effects in Phase II studies, including up to 22.7% mean body-weight reduction at 48 weeks at the highest dose. It is currently being evaluated in Phase III in adults with obesity or overweight, with or without type 2 diabetes.

3. Company Overview: NeuroBiogen Co., Ltd

NeuroBiogen Co., Ltd. is a South Korea-based pharmaceutical biotechnology company focused on developing innovative therapies for diseases with significant unmet medical needs. The company specializes in neurodegenerative and metabolic diseases, with an emphasis on first- and best-in-class drug development. Its lead candidate is being investigated for obesity and several neurological disorders, including Alzheimer’s disease. NeuroBiogen combines internal R&D capabilities with partnerships to advance its drug candidates toward global development and commercialization.

Product Description: KDS2010

KDS2010 is an investigational reversible monoamine oxidase-B (MAO-B) inhibitor being developed by NeuroBiogen for the treatment of obesity. It is designed as an oral, once-daily therapy, with the potential to address obesity through a mechanism distinct from incretin-based treatments. KDS2010 is being evaluated for its effects on body weight, body composition, metabolic parameters, and MAO-B activity. The ongoing Phase IIa study is assessing 120 mg, 180 mg, and 240 mg doses in adults with overweight or obesity.

4. Company Overview: Wave Life Sciences Ltd.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company founded in 2012 and headquartered in Cambridge, Massachusetts, with its parent company incorporated in Singapore. The company specializes in RNA medicines, leveraging its proprietary PRISM® platform and multiple RNA-targeting modalities, including RNA editing, RNA interference, splicing, and antisense silencing. Its pipeline spans obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, among other disorders. Wave is focused on developing first- or best-in-class RNA therapeutics for both rare and common diseases with significant unmet medical needs.

Product Description: WVE-007

WVE-007 is an investigational INHBE-targeting GalNAc-siRNA therapy developed by Wave Life Sciences for the treatment of obesity and cardiometabolic diseases. It is designed to silence INHBE mRNA, thereby reducing Activin E signaling and promoting fat loss while preserving lean muscle mass. WVE-007 is administered by subcutaneous injection and has demonstrated reductions in visceral and total body fat in early clinical studies. The ongoing Phase I/IIa INLIGHT trial is evaluating its safety, pharmacokinetics, pharmacodynamics, and effects on body composition and weight in adults with overweight or obesity.

5. Company Overview: Ascletis Pharma Inc.

Ascletis Pharma Inc. is a China-based, R&D-driven biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative therapeutics. The company has evolved into a fully integrated biopharmaceutical platform covering the entire value chain from drug discovery through commercialization. Its current focus is primarily on metabolic diseases, supported by proprietary technologies including AI-assisted drug discovery and ultra-long-acting drug platforms. Ascletis is listed on the Hong Kong Stock Exchange and is developing a broad pipeline of small molecules and peptide-based therapies.

Product Description: ASC36

ASC36 is an investigational next-generation amylin receptor peptide agonist being developed by Ascletis Pharma for the treatment of obesity. It is designed as a long-acting injectable therapy, with potential dosing once monthly to once quarterly. By activating amylin receptors, ASC36 is intended to regulate appetite and promote weight loss through effects on satiety and energy balance. In August 2026, Ascletis initiated a Phase I study in the US following FDA clearance of its IND application.

6. Company Overview: Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a US-based biopharmaceutical company founded in 1992 and headquartered in San Diego, California, focused on discovering, developing, and commercializing innovative medicines. The company primarily targets neurological, neuroendocrine, neuropsychiatric, and immunological disorders, with an emphasis on underserved patient populations. Its portfolio includes FDA-approved therapies for conditions such as tardive dyskinesia, Huntington’s disease-associated chorea, congenital adrenal hyperplasia, and endometriosis. Neurocrine also maintains a diversified pipeline of small molecules, peptides, proteins, antibodies, and gene therapies across multiple stages of development.

Product Description: NBIP-'1968

NBIP-'1968 is an investigational long-acting GLP-1/GIP/glucagon receptor triple agonist being developed by Neurocrine Biosciences for the treatment of obesity. It is designed for once-weekly subcutaneous administration, simultaneously targeting three complementary metabolic pathways involved in appetite regulation, energy balance, and glycemic control. The candidate incorporates balanced glucagon receptor activity with the aim of maximizing metabolic benefits while supporting tolerability. In August 2026, Neurocrine initiated a Phase I first-in-human study to evaluate its safety and tolerability in adults with varying BMI categories.

7. Company Overview: Alveus Therapeutics, Inc.

Alveus Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2023 and focused on developing next-generation therapies for obesity and metabolic diseases. The company aims to address limitations of existing treatments, including weight regain, tolerability, and treatment burden, through differentiated long-acting therapies. Its lead program, ALV-100, is a bifunctional GIP receptor antagonist/GLP-1 receptor agonist fusion protein, supported by a broader amylin-focused pipeline. Alveus is headquartered in Philadelphia, with R&D operations in Copenhagen, and is backed by leading life-sciences investors.

Product Description: ALV-100

ALV-100 is an investigational bifunctional GIP receptor antagonist/GLP-1 receptor agonist fusion protein being developed by Alveus Therapeutics for the treatment of obesity. It is designed to combine GLP-1 receptor agonism with GIP receptor antagonism to promote weight loss and potentially improve metabolic health. ALV-100 is administered by subcutaneous injection and is being evaluated for its effects on body weight, pharmacokinetics, and pharmacodynamics. The ongoing Phase Ib study is assessing its safety and tolerability in adults with overweight or obesity, with or without type 2 diabetes.

Further product details are provided in the report……..

Obesity Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: Obesity Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• Obesity Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy and, development stage).

Obesity Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Obesity Clinical Trial Assessment

• Clinical Trial Analysis
• Clinical Trial Design Analysis
• Sponsor and Geographical Analysis

• Obesity Clinical Trial Analysis

The report provides a comparative assessment of clinical trial analysis (by status, development stage, therapy area, enrolled participants by age, study completion year, end point status).

• Obesity Clinical Trial Design Analysis

The report provides a structured comparative assessment of clinical trial design analysis (by allocation, interventional model, enrolled participants by status, masking).

• Sponsor and Geographical Analysis

The report provides a comparative assessment of sponsor and geographical analysis (by top sponsors, developmental stage, clinical trials sponsored by countries, therapies by countries).

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obesity drugs?
• How many Obesity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obesity?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obesity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obesity and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Eli Lilly and Company
• Novo Nordisk
• Neurocrine Biosciences
• Ascletis Pharma Inc.
• Wave Life Sciences Ltd.
• Genexine
• The United Bio-Technology (Hengqin) Co., Ltd.
• Roche
• MBX Biosciences
• iBio, Inc.
• Viking Therapeutics
• Pfizer
• Suzhou Siran Biotechnology
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• BrightGene Bio-medical technology
• Huons Co., Ltd.
• S1 Biopharma, Inc.
• AbbVie
• Sirius Therapeutics Co., Ltd.
• Suzhou Sanegene Bio Inc.
• Boehringer Ingelheim
• HongKong Curegene Innovation Co., Limited
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Merck Sharp & Dohme LLC
• Hanmi Pharmaceutical Company Limited
• Alveus Therapeutics, Inc.
• Syntis Bio
• Alnylam Pharmaceuticals

Key Products

• Orforglipron
• Retatrutide
• Wegovy
• NBIP-'1968
• ASC36
• WVE-007
• GX-G6
• UBT251
• CT-388
• MBX 4291
• IBIO-600
• VK2735
• Berobenatide
• SA030
• HDM1005
• HS-20136-2
• BGM0504
• HUC2-676
• S1B-509
• ABBV 295
• SRSD384
• SGB-7342
• BI 3034701
• CG-0416
• SYH2082
• MK-4082
• HM17321
• ALV-100
• SYNT-101
• ALN-6222